Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study

Authors
Hong, Keun-SikKwon, Sun UckPark, Jong-HoCha, Jae-KwanJung, Jin-ManKim, Yong-JaeLee, Kyung BokSohn, Sung IlLee, Yong-SeokRha, Joung-HoKwon, Jee-HyunHan, Sang WonKim, Bum JoonKoo, JaseongChoi, Jay CholSung, Sang MinLee, Soo JooPark, Man-SeokAhn, Seong HwanBang, Oh YoungHwang, Yang-HaNam, Hyo SukPark, Jong-MooBae, Hee-JoonKim, Eung GyuLee, Kyung-YulOh, Mi Sun
Issue Date
7월-2021
Publisher
KOREAN NEUROLOGICAL ASSOC
Keywords
blood pressure; prevention and control; stroke; fimasartan
Citation
JOURNAL OF CLINICAL NEUROLOGY, v.17, no.3, pp.344 - 353
Indexed
SCIE
SCOPUS
KCI
Journal Title
JOURNAL OF CLINICAL NEUROLOGY
Volume
17
Number
3
Start Page
344
End Page
353
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/137245
DOI
10.3988/jcn.2021.17.3.344
ISSN
1738-6586
Abstract
Background and Purpose Blood pressure (BP) control is strongly recommended, but BP control rate has not been well studied in patients with stroke. We evaluated the BP control rate with timasartan-based antihypertensive therapy initiated in patients with recent cerebral ischemia. Methods This multicenter, prospective, single-arm trial involved 27 centers in South Korea. Key inclusion criteria were recent cerebral ischemia within 90 days and high BP [systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg]. BP lowering was initiated with fimasartan. BP management during the follow-up was at the discretion of the responsible investigators. The primary endpoint was the target BP goal achievement rate (<140/90 mm Hg) at 24 weeks. Key secondary endpoints included achieved BP and BP changes at each visit, and clinical events (ClinicalTriaLs.gov Identifier: NCT03231293). Results Of 1,035 patients enrolled, 1,026 were included in the safety analysis, and 951 in the efficacy analysis. Their mean age was 64.1 years, 33% were female, the median time interval from onset to enrollment was 10 days, and the baseline SBP and DBP were 162.3 +/- 16.0 and 92.2 +/- 12.4 mm Hg (mean +/- SD). During the study period, 55.5% of patients were maintained on fimasartan monotherapy, and 44.5% received antihypertensive therapies other than fimasartan monotherapy at at least one visit. The target BP goal achievement rate at 24-week was 67.3% (48.6% at 4-week and 61.4% at 12-week). The mean BP was 139.0/81.8 +/- 18.3/11.7, 133.8/79.2 +/- 16.4/11.0, and 132.8/78.5 +/- 15.6/10.9 mm Hg at 4-, 12-, and 24-week. The treatment-emergent adverse event rate was 5.4%, including one serious adverse event. Conclusions Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE